Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 166 clinical trials
Featured trial
PLUS 1 Study

PLUS 1 Study

  • 249 views
  • 08 Nov, 2020
  • 1 location
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 0 views
  • 20 Jun, 2022
  • 1 location
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of treatment with crinecerfont. Duration of

classic congenital adrenal hyperplasia
deficiency
21-ohd
  • 3 views
  • 07 Oct, 2022
  • 39 locations
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment (CAHtalyst)

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of …

deficiency
21-ohd
  • 123 views
  • 18 Oct, 2022
  • 60 locations
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen. Optional open label treatment extension period up to 240 weeks with 200mg tildacerfont QD.

prednisolone
prednisone
17-hydroxyprogesterone
deficiency
21-ohd
  • 28 views
  • 07 Oct, 2022
  • 57 locations
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.

prednisone
prednisolone
deficiency
21-ohd
  • 10 views
  • 07 Oct, 2022
  • 55 locations
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME)

, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21

prednisolone
dexamethasone
21-ohd
prednisone
adrenal insufficiency
  • 56 views
  • 14 Apr, 2022
  • 1 location
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.

oral hydrocortisone
classic congenital adrenal hyperplasia
21-ohd
  • 6 views
  • 07 Oct, 2022
  • 3 locations
  • 2 views
  • 20 Jun, 2021
  • 3 locations
  • 0 views
  • 04 Oct, 2022
  • 6 locations